This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT ID: NCT06758401
Last Updated: 2025-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
714 participants
INTERVENTIONAL
2025-07-23
2029-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is seeking for participants who:
* Are confirmed to have NSCLC (Stage 3 or 4).
* Have PD-L1 levels in more than 50% of the cancer cells.
All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab.
Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
NCT02220894
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
NCT04515979
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
NCT04274907
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab Monotherapy
Participants will receive pembrolizumab, administered as an IV infusion.
Pembrolizumab
Anti-PD-(L)1
Sigvotatug Vedotin with Pembrolizumab
Participants will receive Sigvotatug Vedotin, administered as an IV infusion and pembrolizumab, administered as an IV infusion.
Sigvotatug Vedotin
MMAE-Antibody Drug Conjugate targeting Integrin Beta-6
Pembrolizumab
Anti-PD-(L)1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sigvotatug Vedotin
MMAE-Antibody Drug Conjugate targeting Integrin Beta-6
Pembrolizumab
Anti-PD-(L)1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Have pathologically confirmed Stage IIIB or IIIC NSCLC and not be a candidate for surgical resection or definitive chemoradiation, or Stage IV NSCLC per the AJCC Staging Manual (Version 8.0) and the UICC Staging System (Eighth edition).
2. Participants with non-squamous histology must have documented negative test results for EGFR, ALK, and ROS1 AGAs and no known AGAs in NTRK, BRAF, RET, MET, or other AGAs with approved front-line therapies per local standard of care.
3. Large cell neuroendocrine carcinoma is excluded.
4. Candidate for treatment with pembrolizumab monotherapy per local guidelines.
2. Tumor has PD-L1 expression in ≥50% of tumor cells (TPS ≥50%) as determined by local testing
3. Measurable disease based on RECIST v1.1 per investigator.
4. Resolution of acute effects of any prior therapy to either baseline severity or NCI CTCAE Grade 1 or less (except for AEs not constituting a safety risk in the investigator's judgment), unless otherwise excluded.
Exclusion Criteria
2. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.
3. Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
4. Known or suspected hypersensitivity, intolerance, or contraindication to any excipient contained in the drug formulation of sigvotatug vedotin or pembrolizumab.
5. Participants with any of the following respiratory conditions:
1. Evidence of noninfectious or drug-induced ILD or pneumonitis
2. Known DLCO (adjusted for hemoglobin) \<50% predicted.
3. Grade ≥3 pulmonary disease unrelated to underlying malignancy
6. Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter \<0.5 cm are permitted.
7. Major surgery (defined as a surgery requiring inpatient hospitalization of at least 48 hours) within 21 days or minor surgery within 7 days prior to first dose of study intervention.
8. Receipt of a live vaccine within 30 days prior to first dose of study intervention.
9. Pre-existing peripheral neuropathy Grade ≥2 per NCI CTCAE v5.0.
10. Uncontrolled diabetes mellitus, defined as HbA1c ≥8.0% or HbA1c between 7.0% and 8.0% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.
11. Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, required a high-dose steroid taper (≥0.5 mg/kg prednisone or equivalent per day) for \>2 weeks, or required treatment with systemic immunosuppressive therapy.
12. History of autoimmune disease that has required systemic treatment in the past 2 years
13. Participants with prior solid organ or bone marrow transplantation.
14. Currently receiving a high-dose steroid (\>10 mg prednisone or equivalent per day) or other immune suppressant or has a condition requiring a chronic high-dose steroid or immune suppressant.
15. Prior and concomitant therapy:
1. Any prior treatment with MMAE-derived drugs or IB6 targeting agents.
2. Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC.
* (Neo)adjuvant anti-PD-(L)1 is allowed if recurrence or progression occurred ≥9 months after the last dose.
* Other (neo)adjuvant or definitive therapy is allowed if recurrence or progression occurred ≥6 months after the last dose.
3. Prior radiotherapy to the lung within 6 months of first dose of study intervention, referencing the last date radiotherapy was received.
4. Chemotherapy, biologics, and/or other antitumor treatment with immunotherapy not specifically prohibited that is completed less than 4 weeks prior to first dose of study intervention, or 2 weeks for palliative radiotherapy.
5. Any prior therapy with an immune-oncology agent directed to a stimulatory or co-inhibitory T-cell receptor
16. History of or current ongoing infection, including participants positive for active HIV, HBV, or HCV.
17. Severe uncontrolled cardiac or cerebrovascular condition within the previous 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center
Fullerton, California, United States
Providence St. Jude Medical Center
Fullerton, California, United States
St. Jude Heritage Medical Group - Fullerton Plaza Multi-Specialty Clinic (Pulmonary Function Test)
Fullerton, California, United States
Intermountain Health Lutheran Hospital
Golden, Colorado, United States
Lutheran Hospital - Cancer Centers of Colorado
Golden, Colorado, United States
Cancer Centers of Colorado St. Mary's Regional Hospital
Grand Junction, Colorado, United States
Intermountain Health St. Mary's Regional Hospital
Grand Junction, Colorado, United States
Intermountain Health
Grand Junction, Colorado, United States
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States
BRCR Global
Plantation, Florida, United States
Hope and Healing Cancer Services
Hinsdale, Illinois, United States
Hope and Healing Cancer Services
New Lenox, Illinois, United States
Maine Medical Center
Portland, Maine, United States
MaineHealth Cancer Care - Scarborough
Scarborough, Maine, United States
MaineHealth Cancer Care and IV Therapy - South Portland
South Portland, Maine, United States
Minnesota Oncology Hematology, PA
Burnsville, Minnesota, United States
Minnesota Oncology Hematology PA
Coon Rapids, Minnesota, United States
M Health Fairview Cancer Clinic-Edina
Edina, Minnesota, United States
Minnesota Oncology Hematology PA
Edina, Minnesota, United States
Minnesota Oncology Hematology PA
Fridley, Minnesota, United States
Minnesota Oncology Hematology PA
Maple Grove, Minnesota, United States
M Health Fairview St. John's Hospital
Maplewood, Minnesota, United States
Minnesota Oncology Hematology PA
Maplewood, Minnesota, United States
Minnesota Oncology Hematology PA
Minneapolis, Minnesota, United States
Hennepin County Medical Center
Minneapolis, Minnesota, United States
North Memorial Health Cancer Center
Robbinsdale, Minnesota, United States
Park Nicollet Frauenshuh Cancer Center
Saint Louis Park, Minnesota, United States
Regions Hospital
Saint Paul, Minnesota, United States
Minnesota Oncology Hematology, P.A. Cornerstone Medical Specialty Center
Woodbury, Minnesota, United States
Jackson Oncology Associates, PLLC
Jackson, Mississippi, United States
Jackson Oncology Associates, PLLC
Jackson, Mississippi, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont
Fremont, Nebraska, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island
Grand Island, Nebraska, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional
Grand Island, Nebraska, United States
Cancer Partners of Nebraska - April Sampson Cancer Center
Lincoln, Nebraska, United States
Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Methodist
Omaha, Nebraska, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan
Omaha, Nebraska, United States
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
Omaha, Nebraska, United States
Hematology Oncology Associates of Rockland
Nyack, New York, United States
Carolina Cancer Research Center
Wilson, North Carolina, United States
Gabrail Cancer Center Research
Canton, Ohio, United States
The University of Texas, MD Anderson Cancer Center - Woodlands
Conroe, Texas, United States
Renovatio Clinical - El Paso
El Paso, Texas, United States
The University of Texas MD Anderson Cancer Center Diagnostic Imaging
Houston, Texas, United States
The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services
Houston, Texas, United States
The University of Texas, MD Anderson Cancer Center- Interventional Radiology
Houston, Texas, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
The University of Texas MD Anderson Cancer Center Clinical Research Imaging
Houston, Texas, United States
The University of Texas, MD Anderson Cancer Center - West Houston
Houston, Texas, United States
Community Clinical Trials
Kingwood, Texas, United States
The University of Texas, MD Anderson Cancer Center - League City
League City, Texas, United States
The University of Texas, MD Anderson Cancer Center - Sugar Land
Sugar Land, Texas, United States
Renovatio Clinical
The Woodlands, Texas, United States
Woodlands Radiology
The Woodlands, Texas, United States
American Oncology Network Vista Oncology Division-West office
Olympia, Washington, United States
American Oncology Network Vista Oncology Division-East office
Olympia, Washington, United States
Fundación Respirar
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Fundacion Estudios Clinicos
Rosario, Santa Fe Province, Argentina
Instituto Argentino de Diagnóstico y Tratamiento (IADT)
Buenos Aires, , Argentina
Centro Urológico Profesor Bengió
Córdoba, , Argentina
Hospital Privado Universitario de Córdoba
Córdoba, , Argentina
Campbelltown Hospital
Sydney, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Townsville University Hospital
Douglas, Queensland, Australia
Gympie Hospital
Gympie, Queensland, Australia
Nambour General Hospital
Nambour, Queensland, Australia
AZ Sint-Maarten
Mechelen, Antwerpen, Belgium
UZ Brussel
Brussels, Bruxelles-capitale, Région de, Belgium
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium
Algemeen Ziekenhuis klina
Brasschaat, , Belgium
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
Liège, , Belgium
Afecc Associacao Feminina Educacao Combate Cancer
Vitória, Espírito Santo, Brazil
Vencer e Oncoclínica
Teresina, Piauí, Brazil
Liga Norte Riograndense Contra o Câncer
Natal, Rio Grande do Norte, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Ijuí, Rio Grande do Sul, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP)
Ribeirão Preto, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, São Paulo, Brazil
MBAL Uni Hospital
Panagyurishte, Pazardzhik, Bulgaria
Complex Oncology Center - Burgas
Burgas, , Bulgaria
Medical Center Futuremeds
Plovdiv, , Bulgaria
MHAT for Women's Health Nadezhda
Sofia, , Bulgaria
Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda EAD
Sofia, , Bulgaria
BC Cancer Abbotsford
Abbotsford, British Columbia, Canada
Centre de Services Ambulatoire de St-Jerome
Saint-Jérôme, Quebec, Canada
Unité de Recherche Clinique du CISSS des Laurentides
Saint-Jérôme, Quebec, Canada
Clínica Alemana Valdivia
Valdivia, Los Ríos Region, Chile
Oncocentro Valdivia
Valdivia, Los Ríos Region, Chile
Oncocentro Apys
Viña del Mar, Región de Valparaíso, Chile
Iceg Clinic
La Florida, Santiago Metropolitan, Chile
Oncovida
Providencia, Santiago Metropolitan, Chile
Profar
Providencia, Santiago Metropolitan, Chile
Clínica Vespucio
Santiago, Santiago Metropolitan, Chile
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Beijing Cancer hospital
Beijing, Beijing Municipality, China
Beijing Chest Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Huizhou Central People's Hospital
Huizhou, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Wuhan Union Hospital Cancer Center
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jinan Central Hospital
Jinan, Shandong, China
Shandong Cancer Hospital
Jinan, Shandong, China
LinYi Cancer Hospital
Linyi, Shandong, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Sichuan Cancer hospital
Chengdu, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Fakultni Thomayerova nemocnice
Prague, Praha 4, Czechia
Fakultni nemocnice v Motole
Prague, Praha 5, Czechia
Nemocnice AGEL Novy Jicin a.s.
Nový Jičín, , Czechia
Centre Antoine-Lacassagne
Nice, Alpes-maritimes, France
CHU Bordeaux Haut-Leveque
Pessac, Aquitaine, France
Centre Hospitalier de Cornouaille Quimper - Concarneau
Quimper, Finistère, France
CHU de Toulouse - Hopital Larrey
Toulouse, Haute-garonne, France
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
Rennes, Ille-et-vilaine, France
Centre de Cancérologie du Grand Montpellier
Montpellier, Languedoc-roussillon, France
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes
Saint-Herblain, Loire-atlantique, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, Loire-atlantique, France
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer
Toulon, Provence-Alpes-Côte d'Azur Region, France
Centre Hospitalier Intercommunal de Créteil
Créteil, Val-de-marne, France
Gustave Roussy
Villejuif, Val-de-marne, France
Centre Hospitalier de Cholet
Cholet, , France
Assistance Publique Hôpitaux de Marseille - Hôpital Nord
Marseille, , France
Hopitaux Universitaires Paris Centre-Hopital Cochin
Paris, , France
Institut Curie
Paris, , France
Klinikum Esslingen
Esslingen am Neckar, Baden-Wurttemberg, Germany
Klinikum Traunstein
Traunstein, Bavaria, Germany
InVO Institut für Versorgungsforschung in der Onkologie
Koblenz, Rhineland-Palatinate, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, Germany
Klinikum Chemnitz - Flemmingstraße
Chemnitz, Saxony, Germany
ohO Research GmbH
Oldenburg in Holstein, Schleswig-Holstein, Germany
Labor Berlin
Berlin, , Germany
Vivantes Humboldt Klinikum Apotheke Nord
Berlin, , Germany
Vivantes Hospital Spandau
Berlin, , Germany
Thoracic General Hospital of Athens "I Sotiria"
Athens, Attikí, Greece
Metropolitan General Hospital
Athens, Attikí, Greece
Metropolitan Hospital
Athens, Attikí, Greece
Hygeia Hospital
Marousi, Attikí, Greece
European Interbalkan Medical Center
Thessaloniki, Thessaloníki, Greece
University General Hospital of Larissa
Larissa, Thessalía, Greece
Errikos Dunant Hospital Center
Athens, , Greece
Agios Loukas Clinic
Thessaloniki, , Greece
Farkasgyepui Tudogyogyintezet
Farkasgyepű, Veszprém megye, Hungary
Komárom-Esztergom Vármegyei Szent Borbála Kórház
Tatabánya, , Hungary
Spandana Oncology Centre (SOC)
Bengaluru, Karnataka, India
Sahyadri Super Speciality Hospital
Pune, Maharashtra, India
Bhakti Vedanta Hospital and Research Institute
Thāne, Maharashtra, India
Venkateshwar Hospital
New Delhi, National Capital Territory of Delhi, India
Rabin Medical Center
Petah Tikva, Central District, Israel
Shaare Zedek Medical Center
Jerusalem, Jerusalem, Israel
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Napoli, Campania, Italy
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
Meldola, Emilia-Romagna, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Orbassano, Piedmont, Italy
Istituto Nazionale Tumori Regina Elena
Rome, ROMA, Italy
Ospedale Isola Tiberina - Gemelli Isola
Rome, ROMA, Italy
Policlinico "G. Rodolico"
Catania, Sicily, Italy
Azienda Ospedaliera San Giuseppe Moscati
Avellino, , Italy
Ospedale San Raffaele
Milan, , Italy
Istituto Europeo di Oncologia IRCCS
Milan, , Italy
Istituto Oncologico Veneto IRCCS
Padua, , Italy
Ehime University Hospital
Tōon, Ehime, Japan
Kurume University Hospital
Kurume, Fukuoka, Japan
Gunma Prefectural Cancer Center
Otashi, Gunma, Japan
National Hospital Organization Asahikawa Medical Center
Asahikawa, Hokkaido, Japan
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
Kanagawa cancer center
Yokohama, Kanagawa, Japan
Mie Chuo Medical Center
Tsu, Mie-ken, Japan
Sendai Kousei Hospital
Sendai, Miyagi, Japan
NHO Kinki Chuo Chest Medical Center
Sakai, Osaka, Japan
The University of Osaka Hospital
Suita, Osaka, Japan
Nippon Medical School Hospital
Bunkyo-ku, Tokyo, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital of JFCR
Koto, Tokyo, Japan
National Hospital Organization Tokyo Medical Center
Meguro-Ku, Tokyo, Japan
Yamagata University Hospital
Yamagata, Yamagata, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, , Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, , Japan
National Hospital Organization Kyoto Medical Center
Kyoto, , Japan
National Hospital Organization Okayama Medical Center
Okayama, , Japan
Osaka International Cancer Institute
Osaka, , Japan
Ziekenhuis St. Jansdal
Harderwijk, Gelderland, Netherlands
St. Antonius Ziekenhuis, locatie Utrecht
Utrecht, , Netherlands
Med-Polonia Sp. z o. o.
Poznan, Greater Poland Voivodeship, Poland
Instytut Genetyki i Immunologii GENIM
Lublin, Lublin Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandow
Poznan, , Poland
Instytut MSF Sp zoo
Lodz, Łódź Voivodeship, Poland
S C Oncocenter Oncologie Clinica S R L
Timișoara, Timiș County, Romania
Nemocnica AGEL Komarno
Komárno, Nitra Region, Slovakia
Fakultna nemocnica Trnava
Trnava, Trnava Region, Slovakia
Vychodoslovensky Onkologicky ustav a.s.
Košice, , Slovakia
POKO Poprad s.r.o.
Poprad, , Slovakia
Chonnam National University Hwasun Hospital
Hwasun-gun, Jeonranamdo, South Korea
Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, South Korea
The Catholic University Of Korea St. Vincent's Hospital
Suwon, Kyǒnggi-do, South Korea
Pusan National University Hospital
Busan, Pusan-kwangyǒkshi, South Korea
Inje University Haeundae Paik Hospital
Haeundae-gu, Pusan-kwangyǒkshi, South Korea
Severance Hospital, Yonsei University Health System
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Boramae Medical Center
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Korea University Guro Hospital
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Kyungpook National University Chilgok Hospital
Deagu, Taegu-kwangyǒkshi, South Korea
CHUAC-Complejo Hospitalario Universitario A Coruña
A Coruña, A Coruña [LA Coruña], Spain
Hospital General Universitario de Elche
Elche, Alicante, Spain
Hospital Universitari Dexeus
Barcelona, Barcelona [barcelona], Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalunya [cataluña], Spain
Hospital Jerez de la Frontera
Jerez de la Frontera, Cádiz, Spain
Hospital Son Llàtzer
Palma, Illes Balears [islas Baleares], Spain
Hospital Insular de Gran Canaria
Las Palmas de Gran Canaria, LAS Palmas, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Comunidad de, Spain
Hospital Clinico de Valencia
Valencia, Valenciana, Comunitat, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, , Spain
Hospital Quironsalud Malaga
Málaga, , Spain
Hospital Quirón Málaga
Málaga, , Spain
Hospital Universitario Virgen Del Rocio
Seville, , Spain
Inselspital Bern
Bern, Canton of Bern, Switzerland
Chi Mei Hospital - Liouying Branch
Tainan, Tainan, Taiwan
National Taiwan University Cancer Center (NTUCC)
Taipei City, Taipei, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Royal Cornwall Hospital
Truro, Cornwall, United Kingdom
St Bartholomew's Hospital
London, London, CITY of, United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-517968-36-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
C5751003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.